MAP2K7 and melanoma: However, two studies evaluating this correlation gave conflicting results with one showing an association between TERT promoter mutations with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy [16]; meanwhile, the other one demonstrated that the TERT promoter mutation was an independent prognostic marker for the poor prognosis MAPK inhibitors-treated melanoma [13].